Lancet oncol: AML is transplanted with Solafini to maintain the efficacy and tolerance of the treatment.

Retrospective studies have shown that Solafinib maintenance therapy may reduce recurrence after transplantation of heterogenetic hematopoietic stem cells in patients with acute myeloid leukemia with FLT3-ITD.
led a team led by Liu Hematology at Southern Medical University conducted an open randomized Phase 3 trial to assess the efficacy and tolerance of Solafini maintenance therapy after transplantation of hematopoietic stem cells from these patients.
end of the year is the cumulative recurrence rate of 1 year.
the trial recruited patients with acute myeloid leukemia who were 18-60 years old with FLT3-ITD for a planned hematopoietic stem cell transplant, and required ECOG to perform 0-2 points, get complete remission before and after the transplant, and recover hematology within 60 days of the transplant.
June 20, 2015 - July 21, 2018, a total of 202 patients were recruited and randomly assigned to the Solafini Maintenance Group (100, Sorafini 400 mg, oral, 2/day) or control group (102).
21.3 months after transplantation.
1 year cumulative recurrence rate was 7.0% and 24.5%, respectively, in the Solafini and control groups (risk ratio of 0.25).
within 210 days of transplantation, the most common 3/4 adverse reactions were infection (24% vs. 24%), acute graft anti-host disease (GVHD 23% vs 21%), chronic GVHD (18% vs 17%) and blood toxicity (15% vs 7%).
treatment-related deaths.
maintenance therapy after transplantation reduces the recurrence of FLT3-ITD acute myeloid leukemia and is well-to-do.
may be a new treatment option for patients with FLT3-ITD acute myeloid leukemia.
.